SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Brand Engagement Network, Inc. engages in the provision of conversational artificial intelligence assistants with the purpose of transforming engagement and analytics for businesses through security-focused, multimodal communication and human-like artificial intelligence assistants. The firm is also involved in delivering highly personalized, multi-modal artificial intelligence engagement with a focus on industries where there is a massive workforce gap and an opportunity to transform how consumers engage with networks, providers, and brands. The company is founded on March 14, 2024 and is headquartered in Jackson, WY.

Brand Engagement Network Inc

Brand Engagement Network Inc. (BNAI) is experiencing a massive surge driven by an extreme short squeeze, fueled by its exceptionally low public float and recent reverse stock split. The community is actively discussing significant parabolic gains and drawing comparisons to past high-volatility meme stocks, with strong FOMO present alongside warnings of extreme speculation. This intense retail interest is amplified by the company's position within the broader AI sector.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth (USAR) is experiencing significant attention following reports of a substantial $1.6 billion government investment, including an equity stake and debt financing, aimed at bolstering domestic critical mineral production for national security. The community is actively discussing the deal's potential to drive a major revaluation of the company, with many anticipating substantial price appreciation and positive ripple effects across the broader rare earth sector.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigetti Computing is trending amid news of an $8.4 million order for its 108-qubit quantum computer from India, which bullish investors interpret as a crucial commercial step. However, community discussions are sharply divided, with many highlighting recent delays in the same system's general availability and questioning the company's high valuation amidst ongoing cash burn. The broader quantum sector continues to grapple with the tension between its immense long-term potential and current challenges in profitability and technological scaling.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

United States Antimony (UAMY) is generating significant buzz following its acquisition of a critical minerals flotation facility and news that the State of Alaska has purchased shares, fueling strong bullish sentiment within the community. Investors are highlighting the company's active production and military contracts for antimony, believing it's undervalued and positioned for further government investment amid a heightened focus on securing domestic critical mineral supply chains.

Dogelon Mars

Dogelon Mars ($ELON) is trending amid polarized community sentiment, following a recent exchange delisting by Bitget and continued discussion around its long-promised "Great Burn" and metaverse utility. While some investors view current price levels as an accumulation opportunity, linking its potential to broader crypto rallies and Elon Musk's brand, a significant portion of the community considers it a "dead coin" or "pump and dump" due to persistent underperformance and perceived management failures.

BitGo Holdings, Inc. provides cryptocurrency custody solutions. It offers self-custody wallet, qualified custody, liquidity and prime, and infrastructure-as-a-service. The company was founded by Michael Belshe in 2013 and is headquartered in Palo Alto, CA.

BitGo Holdings Inc. - Ordinary Shares - Class A

BitGo Holdings (BTGO) is a major talking point after its market listing, experiencing significant price movements that have led to divided community sentiment. While many are pointing to substantial short interest and the potential for a squeeze, others are actively discussing the company's established role in crypto infrastructure, national bank charter, profitability, and perceived high-level government connections as a strong long-term value proposition amidst initial investor concerns.

Movano, Inc. is a health-focused technology company. The firm uses non-invasive technology to enable individuals and their healthcare partners to measure and manage their health conditions. It offers solutions through the app, the cloud, the wearable, and the sensor. The company was founded by Michael Aaron Leabman in January 2018 and is headquartered in Pleasanton, CA.

Movano Inc

Movano Inc. (MOVE) is trending following news that its merger partner, Corvex, secured a long-term NVIDIA H200 GPU deployment for AI development. This has ignited significant community excitement around the stock's exceptionally low float and its connection to the booming AI sector, with many anticipating substantial upside while some caution about the direct nature of the Nvidia relationship.

Redwire Corp. manufactures and supplies space equipment. It offers critical space solutions and reliability components for the next generation space economy with IP for solar power generation and in-space 3D printing and manufacturing. It assists its customers in solving challenges of future space missions. The company was founded in 2020 and is headquartered in Jacksonville, FL.

Redwire Corporation

Redwire Corp

Redwire (RDW) is experiencing heightened investor interest due to its strategic positioning within critical national defense initiatives, including the "Golden Dome" missile defense system, and its expanding partnerships across the burgeoning space sector. The community is actively discussing the company's strong contract potential and cutting-edge space infrastructure, from advanced solar arrays to in-space manufacturing and healthcare, often drawing parallels to established tech leaders.

NioCorp Developments Ltd. engages in the evaluation, acquisition, exploration, and development of mineral deposits. It focuses on a super alloy materials project in Nebraska for producing niobium, scandium, and titanium. The company was founded on February 27, 1987, and is headquartered in Centennial, CO.

NioCorp Developments Ltd

NioCorp Developments is currently trending following recent positive assay updates confirming enhanced mineralization, alongside strategic moves towards becoming a vertically integrated U.S. scandium alloy supplier. The community is actively discussing strong institutional accumulation and anticipation of imminent EXIM loan approval, positioning NB as a crucial domestic provider of niobium, scandium, and rare earths amid growing national supply chain priorities.

The Kraft Heinz Co. engages in the manufacture and market of food and beverage products. It operates through the North America and International geographical segments. The company was founded on July 2, 2015, and is headquartered in Pittsburgh, PA.

Kraft Heinz Co

Kraft Heinz is a hot topic, with the community actively debating the implications of a major institutional investor's potential stake divestment and an upcoming strategic company split. Many see the current valuation as a deep discount, highlighting its strong brand portfolio, attractive dividend yield, and defensive appeal amidst broader market uncertainties. A significant sentiment suggests the stock is being deliberately suppressed, presenting a compelling opportunity for value-focused investors.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Atossa Genetics Inc. (NASDAQ:ATOS) Receives Consensus Recommendation of "Hold" from Analysts

Atossa Genetics Inc. (NASDAQ:ATOS - Get Free Report) has received a consensus rating of "Hold" from the five research firms that are covering the company, Marketbeat.com reports. Two analysts have...

Atossa Therapeutics' Founder and CEO Steven Quay, M.D., Ph.D. Named One of The Top 50 Healthcare Technology CEOs of 2025

Atossa Therapeutics' Founder and CEO Steven Quay, M.D., Ph.D. Named One of The Top 50 Healthcare Technology CEOs of 2025 Atossa Therapeutics' Founder and CEO Steven Quay, M.D., Ph.D. Named One of The...

Atossa Secures FDA Orphan Drug Designation For (Z)-Endoxifen In Duchenne Muscular Dystrophy

(RTTNews) - Atossa Therapeutics, Inc. (ATOS) announced that the U.S. Food and Drug Administration's Office of Orphan Products Development (OOPD) has granted Orphan Drug Designation to (Z)-endoxifen...

Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystrophy

Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystrophy Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen...

<ul class="summary-bullets"><li>ODD is granted to a drug or biological product intended to prevent, diagnose, or treat a rare disease or condition.</li><li>The designation provides Atossa with incentives such as tax credits for qualified clinical trial expenses, exemptions from certain FDA user fees, and potential for seven years of market exclusivity.</li><li>(Z)-Endoxifen is a targeted therapy developed to disrupt estrogen signaling by inhibiting and degrading estrogen receptors.</li></ul>Shares of Atossa Therapeutics (ATOS) rose 10% in premarket trading on Friday, after the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to its investigational therapy (Z)-Endoxifen for Duchenne Muscular Dystrophy.<h2 class="st-heading-2">Importance Of ODD Approval</h2>The FDA can grant ODD to a drug or biological product intended to prevent, diagnose, or treat a rare disease or condition.The designation provides sponsors (Atossa) with several incentives, including tax credits for qualified clinical trial expenses, exemptions from certain FDA user fees, and the potential for seven years of market exclusivity following approval. ODD is a separate process from seeking approval or licensing.Last week, the FDA issued a “Study May Proceed” letter for the company’s metastatic breast cancer trial under an IND for (Z)-endoxifen, a decision the company said supports expanding the drug’s use in ER+/HER2- metastatic breast cancer.<h2 class="st-heading-2">What Is This Investigational Drug?</h2>(Z)-Endoxifen is a selective estrogen receptor modulator designed to inhibit and degrade estrogen receptors, including hormone-resistant cancers. The company is also exploring the drug’s broader therapeutic potential across additional disease pathways. The pharmaceutical company is developing an oral formulation designed to pass through the stomach unchanged, so it doesn’t become inactive.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/ATOS">ATOS</a> on Stocktwits remained in the ‘bearish’ territory over the past 24 hours, despite the sharp premarket climb.<img src="https://news.stocktwits-cdn.com/ATOS_jpg_2ffe3fc376.webp" alt="ATOS.jpg">One user believes that the news could push the stock price above $1. It is currently at $0.6.<stembedurl>https://stocktwits.com/virviru/message/642015533</stembedurl>Atossa will hold a shareholder meeting on January 20 to propose, among other items, a reverse split of its common stock at a ratio of 5:1 to 20:1.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/nasdaq-sp500-futures-higher-mu-nvda-ntla-asts-msft-stocks-to-watch/cmUlVD2R4Jz">Nasdaq, S&amp;P 500 Futures Edge Higher Ahead Of Long Weekend: Why NVDA, MU, NTLA, ASTS Are On Traders' Radar Today</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

 In this photo illustration, the Atossa Therapeutics logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Why Did ATOS Stock Jump 10% In Pre-Market Today?

The U.S. Food and Drug Administration granted Orphan Drug Designation to its (Z)-Endoxifen therapy for DMD.

Equity

Atossa Therapeutics Receives FDA "Study May Proceed" Letter for (Z)-Endoxifen Investigational New Drug Application for Metastatic Breast Cancer

Atossa Therapeutics Receives FDA 'Study May Proceed' Letter for (Z)-Endoxifen Investigational New Drug Application for Metastatic Breast Cancer Atossa Therapeutics Receives FDA 'Study May Proceed...

Atossa Genetics Inc. (NASDAQ:ATOS) Sees Large Increase in Short Interest

Atossa Genetics Inc. (NASDAQ:ATOS - Get Free Report) was the recipient of a large increase in short interest in December. As of December 15th, there was short interest totaling 2,284,050 shares, an...

Shares of Atossa Genetics Inc. (NASDAQ:ATOS - Get Free Report) have received an average recommendation of "Hold" from the five research firms that are covering the company, MarketBeat.com reports...

Atossa Genetics (NASDAQ:ATOS) Share Price Passes Below 200 Day Moving Average - Should You Sell?

Atossa Genetics (NASDAQ:ATOS) Share Price Passes Below 200-Day Moving Average - Here's What Happened...

Atossa Therapeutics Wins 2025 Clinical Trials Arena Research and Development Excellence Award in Precision Endocrine Therapy Category

Atossa Therapeutics Wins 2025 Clinical Trials Arena Research and Development Excellence Award in Precision Endocrine Therapy Category Atossa Therapeutics Wins 2025 Clinical Trials Arena Research and...

Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.

Atossa Therapeutics Inc

$MSFT

$AAPL

$TSLA

$META

Earnings season is heating up, and several major companies report next week, including Microsoft, Apple, Tesla, and Meta. Which are you most excited for?

Which earnings report are you most excited for next week? 
 
Drop a comment for others.

ATOS
Atossa Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ATOS News

ATOSAtossa Therapeutics Inc